The future of ALK‐positive ALCL is to define the role of targeted therapies by developing a ‘chemotherapy‐free’ approach for patients with standard‐risk ALCL and an integrated approach to cure patients with high‐risk ALCL. This evidence concerns the gene ALK and anaplastic large cell lymphoma.